Skip to search formSkip to main content
You are currently offline. Some features of the site may not work correctly.

KO 202125

Known as: KO-202125, KO202125 
 
National Institutes of Health

Related topics

Related topics

1 relation

Broader (1)

Isoindoles

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2011
2011
The in vitro and in vivo anti‐tumor effect of KO‐202125, a sauristolactam derivative, as a novel epidermal growth factor receptor inhibitor in human breast cancer
Epidermal growth factor receptor (EGFR) is one of the most promising targets for cancer therapy. Here, we show the in vitro and… Expand
2010
2010
KO-202125, a sauristolactam derivate, induces apoptosis to prevent KB human oral squamous carcinoma cells through inhibition of cyclooxygenase-2 expression
In a previous study, we demonstrated that cyclooxygenase-2 (COX-2) is overexpressed in Korean patients having oral cancer. The… Expand
2008
2008
KO-202125, a sauristolactam derivate, induce Apoptosis and G2/M Cell cycle arrest in human oral squamous carcinoma cells through inhibition of cyclooxygenase-2 expression
 
By clicking accept or continuing to use the site, you agree to the terms outlined in our Privacy Policy, Terms of Service, and Dataset License
ACCEPT & CONTINUE